GlassScriptPhysician profile
Steve K Nam
NPI 1174788061
$15,336.72
in general payments reported to CMS, 2019-2025
58 companies · $2,452 in 2025
The $2,452 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,740 · 2020: $1,672 · 2021: $2,461 · 2022: $2,077 · 2023: $2,557 · 2024: $2,378 · 2025: $2,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,387.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,089.92 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,383.24 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $1,292.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,281.87 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,018.08 | 2019-2025 | Jardiance, Spiriva Respimat, Ofev |
| Lilly USA, LLC | $640.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $520.60 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $473.25 | 2020-2025 | Verquvo, Gardasil 9, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $465.21 | 2021-2025 | |
| Daiichi Sankyo INC. | $446.85 | 2020-2025 | Injectafer |
| Glaxosmithkline, LLC. | $446.00 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $411.35 | 2019-2023 | |
| Astellas Pharma US INC | $349.05 | 2019-2025 | Veozah |
| Amgen INC. | $342.92 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Janssen Pharmaceuticals, INC | $310.79 | 2019-2025 | Spravato |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.28 | 2019-2025 | Xifaxan |
| Allergan, INC. | $271.72 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.07 | 2019-2023 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $217.73 | 2019-2025 | Ajovy, Austedo Xr |
| Sumitomo Pharma America, INC. | $203.22 | 2023-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $194.21 | 2019-2022 | |
| Exact Sciences Corporation | $184.22 | 2023-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $164.19 | 2020-2025 | Korlym |
| Azurity Pharmaceuticals, INC. | $159.64 | 2024-2025 | Edarbyclor |
| Biohaven Pharmaceuticals, INC. | $156.83 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $123.75 | 2019-2025 | Eliquis, Camzyos |
| Nestle Healthcare Nutrition INC. | $115.41 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $97.87 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $95.77 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $91.63 | 2019-2024 | Rexulti, Jynarque |
| Optinose US, INC. | $90.45 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $89.77 | 2023-2025 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $81.89 | 2022-2023 | Quviviq |
| Neurocrine Biosciences, INC. | $78.33 | 2023-2025 | Ingrezza |
| Dexcom, INC. | $73.03 | 2024-2025 | Dexcom G6 Transmitter |
| Vivus LLC | $72.35 | 2024-2025 | Qsymia |
| Ironwood Pharmaceuticals, INC | $70.21 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $65.53 | 2019-2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $61.94 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $61.24 | 2022 | |
| Aimmune Therapeutics, INC. | $54.44 | 2024-2025 | Zenpep |
| Inspire Medical Systems, INC. | $50.61 | 2023-2025 | Inspire |
| Axsome Therapeutics, INC. | $47.19 | 2025 | Auvelity |
| Seqirus USA INC | $47.15 | 2022-2024 | Fluad, Flucelvax |
| Jazz Pharmaceuticals INC. | $45.80 | 2020-2021 | |
| Lundbeck LLC | $40.35 | 2024-2025 | Rexulti |
| Abbott Laboratories | $30.39 | 2022-2024 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $29.63 | 2023 | Unithroid |
| Tonix Medicines, INC. | $23.05 | 2025 | Tonmya |
| Medtronic, INC. | $20.73 | 2025 | Inceptiv |
| Biogen, INC. | $18.22 | 2022 | |
| Alkermes, INC. | $16.59 | 2023 | Aristada, Lybalvi |
| Echosens North America, INC. | $15.37 | 2025 | Fibroscan |
| Almatica Pharma LLC | $15.21 | 2022 | |
| Tactile Systems Technology INC | $14.27 | 2025 | Nimbl, Flexitouch Plus |
| Sanofi Pasteur INC. | $13.86 | 2022 | |
| Eisai INC. | $13.16 | 2021 | |
| Sunovion Pharmaceuticals INC. | $10.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Nam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.